Kristen Sadana, MD
Psychiatry · Danbury, CTNPI 1548522022
Payments from drug & device makers
Across 165 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$773
- Takeda Pharmaceuticals U.S.A., Inc.$509
- Lundbeck LLC$353
- Otsuka America Pharmaceutical, Inc.$280
- Vanda Pharmaceuticals Inc.$166
- Neurocrine Biosciences, Inc.$161
- plus $794 from 14 others
What the payments were for
- Food & beverage$3,036100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $773 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $509 |
| Lundbeck LLC | 19 | $353 |
| Otsuka America Pharmaceutical, Inc. | 15 | $280 |
| Vanda Pharmaceuticals Inc. | 8 | $166 |
| Neurocrine Biosciences, Inc. | 9 | $161 |
| Shire North American Group Inc | 8 | $147 |
| Ironshore Pharmaceuticals Inc. | 6 | $108 |
| Teva Pharmaceuticals USA, Inc. | 3 | $70 |
| Jazz Pharmaceuticals Inc. | 4 | $68 |
| Tris Pharma Inc | 4 | $65 |
| Avanir Pharmaceuticals, Inc. | 4 | $61 |
| Neos Therapeutics, LP | 3 | $55 |
| Adlon Therapeutics L.p. | 3 | $51 |
| Vertical Pharmaceuticals, LLC | 3 | $48 |
| Johnson & Johnson | 2 | $43 |
| Eisai Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Alfasigma USA, Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$3,036 in reported general payments places this provider in the 85th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 24 | $7,991 |
| Duloxetine Hcl | 35 | $5,464 |
| Ziprasidone Hcl | 13 | $2,419 |
| Bupropion XlBupropion Hcl | 59 | $1,327 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 44 | $1,178 |
| Clonazepam | 100 | $1,058 |
| Bupropion Hcl | 21 | $958 |
| Eszopiclone | 23 | $925 |
| Lamotrigine | 66 | $826 |
| Alprazolam | 54 | $812 |
| Fluoxetine Hcl | 82 | $798 |
| Pilocarpine Hcl | 12 | $744 |
| Buspirone Hcl | 31 | $694 |
| Trazodone Hcl | 38 | $662 |
| Guanfacine Hcl ErGuanfacine Hcl | 28 | $645 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Danbury
- Donald AmmermanDanbury$1.5M
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Ghazi AsaadDanbury$29K
- Joseph WilliamsDanbury$28K
- Jeffrey SatinoverDanbury$16K
- Vladimir CoricNew Haven$133.7M
- Christopher VandyckNew Haven$20.8M
- Bart SloanNorwalk$6.8M
- Adam MeccaNew Haven$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.